Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Applied Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on February 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by February 18, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Applied Therapeutics made false and misleading statements regarding their clinical trial protocols, which created a false impression of compliance with good clinical practices [5]. - It is claimed that the company's failure to adhere to proper trial protocols posed a severe risk of FDA rejection of trial data in a New Drug Application [5].
APLT Deadline: APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit